Zoetis inks $255M deal for Abbott's animal health biz; Pfizer cancer pact dampens investors' AZ hopes;

@FiercePharma: Kindred's losses expand as struggling startup boosts R&D efforts. More | Follow @FiercePharma

@CarlyHFierce: $ACT to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue. Release | Follow @CarlyHFierce

> Zoetis ($ZTS)--which recently adopted a poison pill defense after activist investor Bill Ackman acquired an 8.5% stake in the company--has agreed to buy Abbott's ($ABT) animal health business for $255 million. Release | More

> A major cancer deal between Pfizer ($PFE) and Merck KGaA has dampened investors' hopes that the New York drug giant will make another run at AstraZeneca ($AZN). Story

> After a disappointing forecast for its diabetes business and the ousting of its CEO, Sanofi ($SNY) has resumed share repurchasing for the first time since July. Report

> Baring Private Equity Asia has agreed to acquire Japan's Bushu Pharma for $670 million. Report

Medical Device News

@FierceMedDev: UPDATED w/ info from @AdvaMedUpdate Trade agreement with China paves the way for reduction in medical device tariffs. Article | Follow @FierceMedDev

@EmilyWFierce: Reckitt ready to set pharma free in December spinoff, dubbed Indivior. Story | Follow @EmilyWFierce

> Medtronic partners with DaVita as it rolls out CRT meta-analysis data. Story

> LifeBond raising $25M to support development of surgical sealant technology. More

> Report: Hold off on knee replacement until it's necessary. Article

Biotech News

@FierceBiotech: Buzz: Actavis closes in on Big Pharma status with $64B Allergan buyout. Report | Follow @FierceBiotech

@JohnCFierce: Buzz is on. It looks like Allergan found its White Knight deal in Actavis. More likely that Pfizer now follows up? | Follow @JohnCFierce

@DamianFierce: Relevant to today's $PFE + Merck KGaA deal: @FierceBiotech's (now dated) list of the biggest upfront payments ever. More | Follow @DamianFierce

> Actavis bags top 10 Big Pharma status with $66B Allergan buyout. Story

> Bristol-Myers adds to impressive Opdivo survival data with PhIII melanoma results. More

> AstraZeneca's PhIII gout data for lesinurad includes a hit, a strikeout and a missing player. Story

> FDA reverses an embarrassing rejection of Sanofi's Lemtrada, OKs MS drug. Article

CRO News

> Recipharm trades $140M for a Portuguese CDMO. Story

> Catalent makes another buy and ticks up its revenue. Report

> Parexel eyes logistics with latest EU expansion. Story

> WuXi ups its revenue ambitions after M&A and expansion. Article

Biotech IT News

> Pathway Genomics strikes IBM Watson deal and research collaboration. Report

> Ombudsman pushes EMA for explanation of Humira CSR redactions. Item

> Venter's HLI inks deal to access registry of 11,000 twins. Story

> Genomics England seeks teams to analyze data from 100,000 Genomes Project. More

> NHS sets out vision for IT-enabled, research-facilitating future. Article

Animal Health News

> High-flying Heska talks up business overhaul at NYC investor event. More

> Phibro updates guidance for the year, declares quarterly dividend. Report

> Kindred's losses expand as struggling startup boosts R&D efforts. Story

> FDA continues crackdown on equine drugmakers. Item

> Aratana shares sag despite lower-than-expected Q3 loss. Article

And Finally... A growing number of infections in Europe are evading even the most powerful, last-resort antibiotics. More

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…